Table 1.
Demographic characterisctics and laboratory parameters of the study population before and after ciprofibrate treatment
| Before treatment | After treatment | Percent change | |
|---|---|---|---|
| Number of patients | 51 | 51 | – |
| Age (years) | 51.9 ± 8.1 | 51.9 ± 8.1 | – |
| Body weight (kg) | 110 ± 6.9 | 106.4 ± 5.3 | −3.3 |
| Body mass index (kg m−2) | 40.13 ± 2.7 | 39.2 ± 2.4 | −2.3 |
| Glucose (mm) | 6.94 ± 1.15 | 6.87 ± 1.24 | −1.0 |
| Haemoglobin A1c (%) | 7.19 ± 0.94 | 6.76 ± 0.58 | −6.0 |
| Insulin (mU l−1) | 23.37 ± 16.3 | 21.48 ± 11.5 | −8.1 |
| Fibrinogen (g l−1) | 4.12 ± 0.73 | 3.72 ± 0.97* | −9.7 |
| Cholesterol (mmol l−1) | 5.58 ± 0.74 | 5.58 ± 0.82 | 0 |
| LDL-cholesterol (mmol l−1) | 3.36 ± 0.48 | 3.42 ± 0.67 | +1.78 |
| Triglyceride (mmol l−1) | 2.76 ± 0.8 | 2.27 ± 0.6** | −17.7 |
| HDL-cholesterol (mmol l−1) | 0.95 ± 0.21 | 1.2 ± 0.33** | +26.3 |
| Apolipoprotein A1 (g l−1) | 1.35 ± 0.2 | 1.75 ± 0.3** | +29.6 |
| Apolipoprotein B (g l−1) | 1.7 ± 0.45 | 1.56 ± 0.43 | −8.2 |
| Lipoprotein(a) (mg l−1) | 311.9 ± 250 | 304.2 ± 260 | −2.5 |
Values are mean ± SD
**
P < 0.001
*
P < 0.01